Occipital Proton Magnetic Resonance Spectroscopy (1H-MRS) Reveals Normal Metabolite Concentrations in Retinal Visual Field Defects

Background Progressive visual field defects, such as age-related macular degeneration and glaucoma, prevent normal stimulation of visual cortex. We investigated whether in the case of visual field defects, concentrations of metabolites such as N-acetylaspartate (NAA), a marker for degenerative processes, are reduced in the occipital brain region. Methodology/Principal Findings Participants known with glaucoma, age-related macular degeneration (the two leading causes of visual impairment in the developed world), and controls were examined by proton MR spectroscopic (1H-MRS) imaging. Absolute NAA, Creatine and Choline concentrations were derived from a single-voxel in the occipital region of each brain hemisphere. No significant differences in metabolites concentrations were found between the three groups. Conclusions/Significance We conclude that progressive retinal visual field defects do not affect metabolite concentration in visual brain areas suggesting that there is no ongoing occipital degeneration. We discuss the possibility that metabolite change is too slow to be detectable.

[1]  Marco A Zarbin,et al.  Current concepts in the pathogenesis of age-related macular degeneration. , 2004, Archives of ophthalmology.

[2]  H. Schild,et al.  Proton magnetic resonance spectroscopy in Kennedy syndrome. , 1999, Archives of neurology.

[3]  Matthijs Oudkerk,et al.  1H MR spectroscopy of the brain in multiple sclerosis subtypes with analysis of the metabolite concentrations in gray and white matter: initial findings , 2006, European Radiology.

[4]  S. Resnikoff,et al.  Global data on visual impairment in the year 2002. , 2004, Bulletin of the World Health Organization.

[5]  A. Bird,et al.  [Pathogenesis of lesions in late age-related macular disease]. , 2004, Journal francais d'ophtalmologie.

[6]  Pradeep Rajagopalan,et al.  Nuclear magnetic resonance spectroscopy: A review of neuropsychiatric applications , 1995, Progress in Neuro-psychopharmacology and Biological Psychiatry.

[7]  P. Garnier,et al.  N‐Acetylaspartate, a marker of both cellular dysfunction and neuronal loss: its relevance to studies of acute brain injury , 2001, Journal of neurochemistry.

[8]  B. Trapp,et al.  N‐acetylaspartate is an axon‐specific marker of mature white matter in vivo: A biochemical and immunohistochemical study on the rat optic nerve , 2002, Annals of neurology.

[9]  K. Ohtsuka,et al.  N-Acetylaspartate Concentration in the Chiasm Measured by In Vivo Proton Magnetic Resonance Spectroscopy , 2004, Japanese Journal of Ophthalmology.

[10]  Shrikanth S. Narayanan,et al.  Imaging axonal damage in multiple sclerosis by means of MR spectroscopy , 2000, Neurological Sciences.

[11]  N. Jansonius Bayes’ theorem applied to perimetric progression detection in glaucoma: from specificity to positive predictive value , 2005, Graefe's Archive for Clinical and Experimental Ophthalmology.

[12]  R. Weinreb,et al.  Mechanisms of optic nerve damage in primary open angle glaucoma. , 1994, Survey of ophthalmology.

[13]  R. Nickells,et al.  Retinal Ganglion Cell Death in Glaucoma: The How, the Why, and the Maybe , 1996, Journal of glaucoma.

[14]  M. Cynader,et al.  Somatosensory cortical map changes following digit amputation in adult monkeys , 1984, The Journal of comparative neurology.

[15]  S. Leung,et al.  Proton magnetic resonance spectroscopy of late delayed radiation‐induced injury of the brain , 1999, Journal of magnetic resonance imaging : JMRI.

[16]  R. Webster Magnetic Resonance Spectroscopy , 1962, Nature.

[17]  L W Jelinski,et al.  Nuclear magnetic resonance spectroscopy. , 1995, Academic radiology.

[18]  M. Hallett,et al.  Proton magnetic resonance spectroscopic imaging in progressive supranuclear palsy, Parkinson's disease and corticobasal degeneration. , 1997, Brain : a journal of neurology.

[19]  R. Kuzniecky Clinical applications of MR spectroscopy in epilepsy. , 2004, Neuroimaging clinics of North America.

[20]  J. Coyle,et al.  Immunocytochemical localization of N-acetyl-aspartate with monoclonal antibodies , 1991, Neuroscience.

[21]  F Träber,et al.  Proton magnetic resonance spectroscopy of the primary motor cortex in patients with motor neuron disease: subgroup analysis and follow-up measurements. , 1998, Archives of neurology.

[22]  P. Matthews,et al.  Reversible decreases in N‐acetylaspartate after acute brain injury , 1995, Magnetic resonance in medicine.

[23]  F. Träber,et al.  In-vivo proton MR-spectroscopy of the human brain: Assessment of N-acetylaspartate (NAA) reduction as a marker for neurodegeneration , 2002, Amino Acids.

[24]  G. Fein,et al.  Changes of hippocampal N-acetyl aspartate and volume in Alzheimer's disease , 1997, Neurology.

[25]  B. Johansson,et al.  Brain plasticity in health and disease. , 2004, The Keio journal of medicine.